Adverum Biotechnologies (STU:AVU0) Net Income (Continuing Operations) : €-104.45 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Adverum Biotechnologies's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was €-22.80 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €-104.45 Mil.

Adverum Biotechnologies Net Income (Continuing Operations) Historical Data

The historical data trend for Adverum Biotechnologies's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Net Income (Continuing Operations) Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-58.04

-96.59

-128.80

-145.88

-107.44

Adverum Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-27.14	-29.08	-30.81	-21.75	-22.80

Adverum Biotechnologies Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-104.45 Mil.

Adverum Biotechnologies (STU:AVU0) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Adverum Biotechnologies Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (STU:AVU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines